New Zealand

For 2020/2021, New Zealand earmarked some NZ$20.3 billion for healthcare, with efforts centred around disability support services, and bowel, breast, and cervical cancer. 

New Zealand has achieved one of the world’s best results around COVID-19 containment, with just 28 deaths and under 5,000 total cases since the pandemic started.

In 2021, we were recognised as the best performing organisation in a health partnerships supplier report around how well healthcare suppliers performed during COVID-19.

We met demand for semi-automated PCR testing from the very outset of the pandemic in March 2020, delivered the nation’s first fully-automated testing platform in May 2020, and supplied 570,000 PCR tests to the nation’s pathology market, which combined with pooled testing accounts for about 38% of the national testing conducted to date.

Boosting New Zealand’s CPAMS Service

• To combat New Zealand’s high cardiovascular disease rates, we worked with the Pharmaceutical Society of New Zealand, University of Auckland School of Pharmacy, and anticoagulant management service INR Online to roll out CoaguChek test systems to bolster the nation’s Community Pharmacy Anticoagulation Monitoring Service (CPAMS).

Advancing Liver Screening best practices

• To improve early discovery and better treatment outcomes for liver cancer patients, our Roche OneLiver initiative will support national efforts by deepening knowledge and understanding of the use and interpretation of liver function tests among primary healthcare professionals.